The coronavirus pandemic has battered businesses across sectors, including pharma. Supply chain disruptions, pain on the logistics front and commercialization challenges are all playing out across geographies.
COVID-19 And M&A: Multiple Scenarios In Store As World Adapts
Risks And Opportunities Emerging
The coronavirus pandemic could dull pharma M&A activity in the short-term as companies hoard cash and prioritize core activities. But experts say stress in the system could potentially push some firms to cull surplus assets or seek financial/strategic investors, amid a generally tough funding environment. Private equity investors may also find attractive investment opportunities to pursue.
